MXCT

+ Watchlist + Portfolio

MaxCyte, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.07
52-Week Range: $0.64 – $1.87
Market Cap: $113.01M
P/E (TTM): —
EPS (TTM): -0.34
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.73
PEG Ratio: —
Return on Equity: -20.39%
Return on Assets: -10.64%
Gross Margin: 79.23%
Operating Margin: -140.72%
Profit Margin: -114.77%
Current Ratio: 12.26
Debt/Equity: 0.11
Total Debt: $17.25M
Free Cash Flow: $-13.14M
Revenue Growth: -14.50%
Earnings Growth: —
Enterprise Value: $21.99M

MXCT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$44.26M	$41.29M	$38.63M	$33.03M
Cost of Revenue	$5.10M	$4.74M	$7.10M	$6.22M
Gross Profit	$39.16M	$36.55M	$31.53M	$26.80M
Research & Development	$19.51M	$23.82M	$22.23M	$20.82M
Selling, General & Admin	$44.48M	$57.04M	$56.35M	$47.04M
Operating Expenses	$66.52M	$84.84M	$82.72M	$72.09M
Operating Income	-$27.36M	-$48.30M	-$51.20M	-$45.28M
EBITDA	-$24.66M	-$43.73M	-$46.41M	-$40.14M
Pretax Income	-$23.57M	-$37.92M	-$41.05M	-$44.63M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$23.57M	-$37.92M	-$41.05M	-$44.63M
Diluted EPS	-0.23	-0.37	-0.39	-0.42
Diluted Shares	101.70M	103.27M	104.85M	106.43M

MXCT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.06M	$46.51M	$27.88M	$20.07M
Receivables	$13.09M	$5.78M	$4.68M	$3.50M
Inventory	$8.58M	$12.23M	$8.91M	$7.55M
Current Assets	$252.27M	$190.19M	$171.68M	$118.37M
Total Assets	$286.65M	$268.27M	$239.47M	$202.51M
Current Liabilities	$15.43M	$17.86M	$15.78M	$14.27M
Total Debt	$16.09M	$18.74M	$18.03M	$17.94M
Total Liabilities	$32.69M	$36.11M	$33.22M	$31.02M
Retained Earnings	-$137.88M	-$175.80M	-$216.85M	-$261.48M
Shareholders' Equity	$253.97M	$232.17M	$206.25M	$171.49M
Working Capital	$236.84M	$172.34M	$155.91M	$104.10M

MXCT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.78M	-$21.69M	-$27.61M	-$34.41M
Capital Expenditure	-$18.48M	-$3.70M	-$1.65M	-$1.77M
Free Cash Flow	-$33.26M	-$25.39M	-$29.26M	-$36.18M
Depreciation & Amortisation	$2.70M	$4.57M	$4.79M	$5.14M
Stock-Based Compensation	$11.75M	$13.98M	$13.08M	$9.21M
Investing Cash Flow	-$24.82M	$54.98M	$6.93M	$25.93M
Financing Cash Flow	$2.89M	$2.14M	$2.06M	$656.00K
Net Change in Cash	-$36.72M	$35.44M	-$18.62M	-$7.82M

MXCT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$10.39M	$8.51M	$6.83M	$7.30M	$9.65M	$7.27M
Cost of Revenue	$1.50M	$1.52M	$1.60M	$1.61M	$1.57M	$1.68M
Gross Profit	$8.89M	$6.99M	$5.23M	$5.69M	$8.08M	$5.60M
Research & Development	$5.90M	$6.27M	$5.32M	$3.33M	$3.86M	$4.25M
Selling, General & Admin	$14.22M	$13.87M	$9.96M	$8.99M	$9.39M	$10.62M
Operating Expenses	$21.19M	$21.21M	$16.32M	$13.36M	$14.27M	$15.83M
Operating Income	-$12.29M	-$14.23M	-$11.09M	-$7.67M	-$6.18M	-$10.23M
EBITDA	-$11.02M	-$12.93M	-$10.05M	-$5.80M	-$4.92M	-$9.03M
Pretax Income	-$10.26M	-$12.36M	-$12.42M	-$9.60M	-$4.75M	-$8.87M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.26M	-$12.36M	-$12.42M	-$9.60M	-$4.75M	-$8.87M
Diluted EPS	-0.10	-0.12	-0.12	-0.09	-0.04	-0.08
Diluted Shares	105.95M	106.40M	106.61M	106.73M	106.88M	106.82M

MXCT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$23.39M	$15.22M	$12.97M	$20.07M	$14.56M	$15.04M
Receivables	$5.53M	$5.75M	$8.31M	$3.50M	$4.25M	$3.92M
Inventory	$8.27M	$7.93M	$7.61M	$7.55M	$7.63M	$7.80M
Current Assets	$155.75M	$143.22M	$124.64M	$118.37M	$122.94M	$121.27M
Total Assets	$229.96M	$219.75M	$213.48M	$202.51M	$194.47M	$184.67M
Current Liabilities	$12.73M	$11.55M	$16.10M	$14.27M	$10.21M	$9.89M
Total Debt	$18.82M	$18.51M	$18.16M	$17.94M	$17.49M	$17.25M
Total Liabilities	$30.55M	$29.03M	$33.20M	$31.02M	$26.59M	$25.92M
Retained Earnings	-$227.11M	-$239.47M	-$251.89M	-$261.48M	-$266.23M	-$275.11M
Shareholders' Equity	$199.41M	$190.72M	$180.28M	$171.49M	$167.89M	$158.75M
Working Capital	$143.01M	$131.66M	$108.54M	$104.10M	$112.72M	$111.38M

MXCT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$14.41M	-$9.85M	-$7.46M	-$2.69M	-$8.17M	-$4.66M
Capital Expenditure	-$653.00K	-$584.00K	-$300.00K	-$231.00K	-$222.00K	-$62.00K
Free Cash Flow	-$15.06M	-$10.44M	-$7.76M	-$2.92M	-$8.39M	-$4.72M
Depreciation & Amortisation	$1.28M	$1.30M	$694.00K	$1.87M	$1.27M	$1.21M
Stock-Based Compensation	$3.04M	$3.51M	$1.95M	$706.00K	$1.14M	$1.16M
Investing Cash Flow	$9.53M	$1.54M	$5.19M	$9.68M	$2.66M	$6.57M
Financing Cash Flow	$383.00K	$154.00K	$14.00K	$105.00K	$5.00K	-$1.42M
Net Change in Cash	-$4.50M	-$8.16M	-$2.25M	$7.09M	-$5.51M	$485.00K

Market Snapshot

About

MaxCyte develops and commercializes cell-engineering platforms using proprietary electroporation technology for loading cells with biomolecules. The company enables biopharmaceutical developers to create cell-based therapeutics including CAR-T and other immunotherapies.